Cipla aims to double sales of respiratory drugs by 2020
Advertisement
Advertisement
India's fourth-largest drug maker Cipla expects its respiratory drug sales to more than double by 2020.The company aims to achieve this with Seroflo, a version of GSK’s Advair inhaler.
It had launched the product in seven countries so far, and had planned to launch it first in the UK which is touted as the biggest market in the EU for asthma drugs.
Cipla CEO Subhanu Saxena said the company had not changed its sales forecast for Seroflo.
"It would have been nice to be first, obviously. But we are still pretty much in line with our own timelines," Saxena told Reuters in an interview at Cipla's headquarters.
Advertisement
Saxena said the company plans to enter Latin America and Eastern Europe next. "I don't want any market to have more than 20-30 percent exposure for Cipla," he said.
(Image credit: Indiatimes)
Advertisement
- Global stocks rally even as Sensex, Nifty fall sharply on Friday
- In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
- SBI Life Q4 profit rises 4% to ₹811 crore
- IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
- COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market